



BOTHELL, Washington, USA, and SEOONGNAM, Republic of Korea, February 21, 2017 — CMC Biologics, a leading contract manufacturing organization (CMO) for biopharmaceuticals, has announced a strategic partnership with Genexine, a clinical and commercial-stage biopharmaceutical company, to manufacture Genexine's human growth hormone (hGH) product, GX-H9.

GX-H9, being co-developed with Handok under a strategic partnership, is a next-generation, long-acting hGH formulation. The partnership will enable Genexine to accelerate the development and commercialization of GX-H9, which is expected to be a significant milestone in the treatment of growth hormone deficiency.

“We have selected CMC Biologics as our manufacturing partner for GX-H9 because of their demonstrated expertise in the production of complex biologics and their commitment to quality and regulatory compliance,” said Dr. [Name], CEO of Genexine.

Human growth hormone (hGH) is a polypeptide hormone consisting of 121 amino acids. It is produced by the anterior pituitary gland and plays a critical role in the human metabolic system, promoting growth and development.

“As human growth hormone plays a critical role in the human metabolic system, GX-H9 will be critical for the treatment of growth hormone deficiency, particularly in children and adolescents,” said Dr. [Name], CEO of Genexine.

The key function of hGH is growth and is responsible for increasing height. Thus in children and adolescents, hGH deficiency can lead to growth retardation. GX-H9 is designed to provide a long-acting, stable formulation of hGH, which will be a significant improvement over existing products.

About CMC Biologics

CMC Biologics is leading the industry among CMOs in reliability, technical excellence, and quality — Right and On Time. With three facilities in the USA and Europe, the Company provides fully integrated biopharmaceutical development and manufacturing solutions to clients globally. The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical, and commercial production. The Company's wide range of integrated services includes cell line development, bioprocess development, formulation development, and comprehensive analytical testing. Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. More detailed information can be found at www.cmcbio.com.

About Genexine, Inc.

Genexine, Inc., listed on KOSDAQ (095700) since 2009, is a leading biotherapeutics company focused on immuno-oncology and metabolic/autoimmune diseases. Genexine has robust pipelines in clinical and pre-clinical stages based on long-acting Fc fusion technology and therapeutic DNA technology. In the clinical stage, Genexine has GX-H9 (long-acting recombinant human growth hormone, rhGH-hyFc) for both adult and pediatric GHD, currently in multinational phase II trials. GX-188E therapeutic DNA vaccine for HPV-associated diseases is in Phase II in Europe and Korea for Cervical Intraepithelial Neoplasia II/III and plans to enter into Phase 1b/2a trial in cervical cancer with GX-188E in combination Keytruda (anti- PD-1 therapy) of Merck (also known as MSD) 1H of 2017. Founded in 1999, Genexine has over 150 employees and half of them are scientists with MSc or Ph.D. Genexine is located in Pangyo Techno Valley near Seoul, Korea with a branch office in New York. More information can be found at www.genexine.com.

About Handok, Inc.

Handok (Chairman & CEO Young-Jin Kim), listed on KOSPI(002390) is a leading innovation-driven pharmaceutical/health-care company in Korea. Handok develops, manufactures and distributes healthcare solutions to improve the health and quality of human life. Handok has a core business focus on diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, diagnostics and consumer health. Handok, founded in 1954, grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies. More information can be found at www.handok.co.kr.